Prostate Cancer
Selective inhibition of the Ets2 gene shows the potential for stopping cancer
Published in Gene Therapy Weekly, April 17th, 2003
"The transcription factor Ets2 has a role in cancer development and represents an attractive therapeutic target. In this study, we designed a triplex-forming oligonucleotide (TFO) directed to a homopurine:homopyrimidine sequence in the Ets2 promoter. Transcription factors of the Sp family bound to this sequence and mutation of the Sp1 site reduced Ets2 promoter activity," according to recent research from the United States.
"The Ets2-TFO had high binding affinity for the target sequence and inhibited binding of Sp1/Sp3 to the overlapping site. This effect occurred with...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2003-04-17)
More Articles from Gene Therapy Weekly
- Colorectal Cancer
Viral vectors encoding for E2F-1 sensitize cancer cells to camptothecin - Renal Cell Carcinoma
Interferon-beta gene therapy has an antitumor effect against kidney cancer - Cardiac Monitoring
Genetically engineered heart cells provide a new way to check cardiac signals - Gene Repair
DNA pairing is one of the first steps required for targeted nucleotide exchange - Hemophilia A
Gene therapy generates therapeutic levels of factor VIII in animal models - Vector Development
Smac protein could be a payload for gene therapies - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
